NCT03225794 Simian Foamy Virus Transmission to Humans
| NCT ID | NCT03225794 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut Pasteur |
| Condition | Simian Foamy Virus Infection (Disorder) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,600 participants |
| Start Date | 2010-11-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,600 participants in total. It began in 2010-11-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
About three quarters of the viral agents that have emerged recently in humans are considered to originate from other animals. These viruses have often evolved and spread into the human population through various mechanisms after the initial contact that resulted in interspecies transmission. However, knowledge of the initial stages of the emergence of viruses and associated diseases is still limited in many cases. Microbiological monitoring in populations at risk of transmission would provide insights into the initiation and early stages of the emergence process. Nonhuman primates (NHPs) share many genetic, physiological, and microbiological features with humans, and are potential sources of many infectious agents. This has been demonstrated for several simian retroviruses. HIV-1 and 2 are believed to have originated from chimpanzee and mangabey viruses, respectively, found in Central and West Africa. The current distribution of the various molecular subtypes of the HTLV-1 oncogenic retrovirus in Africa is mainly the result of numerous instances of interspecies transmission of STLV-1from NHP species in the distant past. Foamy viruses belong to the Retrovidae family and the Spumavirus genus. They are complex exogenous retroviruses and are very common in many animal species, including primates, cats, cattle, and horses, in which they cause persistent infections. The first aim of the work is to study the epidemiological and molecular aspects of the transmission of foamy viruses from monkeys to humans in populations at risk, such as the inhabitants (especially hunters) in the villages of the dense forests of southern Cameroon. It is an area in which NHPs are still very common, with a great diversity of species. The investigators have already shown that the prevalence of foamy viruses is very high in these monkeys and great apes (gorillas and chimpanzees). Contact between these monkeys and the villagers is very frequent, mainly during hunting. The second aim of the project is to study the clinical and biological features of infected people and investigate intrafamilial transmission from infected index cases.
Eligibility Criteria
Inclusion Criteria: * Living in a rural zone of Cameroon * Being \> 5 yrs old * Having received study information and having provided written consent for self and children, if applicable (for all phases) Exclusion Criteria: * Having refused to provide consent * Being less than 5 years old
Contact & Investigator
Antoine GESSAIN, MD
PRINCIPAL INVESTIGATOR
Institut Pasteur
Frequently Asked Questions
Who can join the NCT03225794 clinical trial?
This trial is open to participants of all sexes, aged 5 Years or older, up to 90 Years, studying Simian Foamy Virus Infection (Disorder). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03225794 currently recruiting?
Yes, NCT03225794 is actively recruiting participants. Contact the research team at antoine.gessain@pasteur.fr for enrollment information.
Where is the NCT03225794 trial being conducted?
This trial is being conducted at Yaoundé, Cameroon.
Who is sponsoring the NCT03225794 clinical trial?
NCT03225794 is sponsored by Institut Pasteur. The principal investigator is Antoine GESSAIN, MD at Institut Pasteur. The trial plans to enroll 1,600 participants.